Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Mast Cell Disorders
Is there any role for immunosuppressive/immunomodulatory therapy used off label for mast cell disorders besides omalizumab?
Related Questions
Do you recommend patients try antihistamines such as oral ketotifen that are not approved in the US but are approved in the EU for MCAS if currently available formulations have not been effective?
Are you requiring markers other than LTE4 to be elevated to diagnose MCAS?
Do you diagnose MCAS if a patient is concurrently on drugs known to cause non-specific mast cell degranulation?
How do you counsel a patient on returning to the care of their PCP when a workup for MCAS has been unrevealing, but the patient insists that they have a mast cell disorder because they respond to antihistamine therapy?
What is the overlap of POTS and Ehlers-Danlos with MCAS?
Do you favor 24 hour urinary metabolites over random urine collection when screening for MCAS?
What treatments do you consider for cholinergic urticaria refractory to high dose H1 blockers and omalizumab?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
Would you ever use dupilumab for atopic dermatitis in a patient who also has EGPA?
How do you reconcile differences between SPT and serum IgE testing for aeroallergens when preparing AIT?
